A dose finding study evaluating the safety and tolerability of CAPecitabine and AflIbercept in patients with unresectable metasTAtic colorectaL cancer deemed unsuitable for doublet/ triplet chemotherapy

Trial Profile

A dose finding study evaluating the safety and tolerability of CAPecitabine and AflIbercept in patients with unresectable metasTAtic colorectaL cancer deemed unsuitable for doublet/ triplet chemotherapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Aflibercept (Primary) ; Capecitabine
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Acronyms CAPITAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Feb 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.
    • 26 Nov 2015 Accrual to date is 37% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top